Boston Scientific Launches the Dakota™ Nitinol Stone Retrieval Device with Opensure™ Handle
Kidney Stone Retrieval Device Enables Physicians to Release and Capture Kidney Stones of Multiple Sizes
Nov 8, 2016
MARLBOROUGH, Mass., (Nov. 8, 2016) – Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the Dakota™ Nitinol Stone Retrieval Device with OpenSure™ Handle at the 34th World Congress of Endourology conference in Cape Town, South Africa. This kidney stone retrieval device is designed to allow physicians to release and capture kidney stones of multiple sizes, from complex stones as large as 10 millimeters to fragments as small as one millimeter.
Kidney stones are one of the most common disorders of the urinary tract, affecting one out of every 11 people and resulting in more than a million visits to healthcare providers and 300,000 emergency room visits in the United States each year.1 Treatment options for kidney stones are determined based on the size, location, and composition of the stone, as well as the associated symptoms. Ureteroscopy is the most common procedure to treat large kidney stones, and involves the use of a ureteroscope and basket retrieval device, such as the Dakota Device, to remove kidney stones.
“The Dakota Retrieval Device with OpenSure Handle offers innovative technology that helps me solve some of the challenges faced during ureteroscopy procedures,” said Roger Sur, M.D., director, Comprehensive Kidney Stone Center, UC San Diego Health, San Diego, CA. “I can extract a variety of stone sizes and compositions and make multiple passes during one procedure to help patients become stone free.”
The Dakota Device design includes multiple features for physicians to address quickly kidney stones with different clinical qualities. The OpenSure Handle is designed to release a large, complex stone which may help reduce procedure time and potentially eliminate complications that can occur during ureteroscopy. Additionally, the nitinol hybrid grasper basket can allow a physician to capture, reposition and remove multiple stones and small fragments in the same procedure. The three-arm nitinol hybrid basket is designed to open and close at full deflection to help physicians reach stones in challenging anatomic locations.
“The Dakota Device with OpenSure Handle is a great complement to our portfolio of stone retrieval devices and builds on other advancements we have made in the field,” said David Pierce, senior vice president and president, Urology and Pelvic Health, Boston Scientific. “As a hybrid basket and grasper, it can help streamline the most challenging stone removal procedures and improve patient outcomes.”
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product launches and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; the closing and integration of acquisitions; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Boston Scientific Corporation
Susie Lisa, CFA
Boston Scientific Corporation
1. Urinary tract stones. In: Litwin MD, Saigal CS, eds. Urologic Diseases in America. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, D.C.: Government Printing Office; 2012. NIH publication 12–7865.